It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Making extra money while in debt can ease financial pressure. Discover practical ways to increase your income and reduce debt.
27,828 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A triple-leveraged ETF focused on semiconductors can swing wildly. This piece breaks down why the direxion daily semi...
Five former Binance investigators allege the exchange processed nearly $1B in Iran sanctions–related transactions aft...
Bitcoin, XRP, and Ethereum show renewed momentum as markets digest regulatory chatter and macro signals. This update ...
Looking for serious cash back without paying a yearly fee? In 2023, several no annual fee cards combined strong categ...
As leveraged ETFs surge in popularity, the active trader dominates turnover in these products, reshaping how markets ...
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
In 2026, hiring stresses sharpen the focus on culture and teamwork. The steve jobs ‘beer test’ stands as a symbol of ...
As markets wobble in 2026, a growing corps of investors is skipping credential checklists in favor of a two-question ...
The Federal Reserve is weighing a major shift to give crypto firms direct access to core settlement rails, potentiall...
Bitcoin briefly traded under $70,000 on June 2, 2026, as Mt. Gox moved a large tranche of BTC. Analysts say the move ...
A 2x leveraged ETF tracking Nvidia fell 12% in a single session while Nvidia itself declined 6.2%, erasing roughly $2...